Kornimate/medical-research-clean huggingface dataset:
the study of nutrition of children and adolescents with gerd

Conditions: GERD in Children; GERD

Summary: this trial is to study the aspects of nutrition in children and adolescents with gerd compared to the sex and age-matched control group

the aim of the study is to assess the differences in nutrition of pediatric patients with gerd compared to the control group. the secondary aim is to study possible associations of the data on nutritional habits revealed with the use of food frequency questionnaire (ffq) and the data of 24-hours oesophageal ph-impedance examination.

Eligibility criteria:
inclusion criteria: * willingness to participate (written informed consent and consent from parents or legal representative according to the local law); * age 6 to 17 years old inclusive, * possibility to assess symptoms, data of the medical history and receive answers to the questions about usual diet. exclusion criteria: * history of abdominal surgery; * presence of varicose veins of the stomach and/or the oesophagus either in medical history or found during the study; * inability to tolerate at least one of the invasive procedures or lacking data of the other instrumental examinations required by protocol; * general condition of the patient making impossible to perform all the examinations or when performing the procedures is not safe and reasonable based on the opinion of the investigator that it may exacerbate the disease flow or put the patient at risk; * intake of medications which may influence the clinical and instrumental data, including, but not limited to: non-steroid anti-inflammatory agents, glucocorticosteroids (except for skin products, if they were used for 2 weeks or less at the time of inclusion into the study), medications affecting adrenergic, acetylcholine receptors, antidepressants, tranquillizers, sedatives, those with known local irritant effect on the gastrointestinal tract mucosa; the use of proton pump inhibitors and h2 receptors blockers are not allowed during the study, a wash-out period for at least 2 weeks is necessary before the enrolment.

Keywords: gastroesophageal reflux weight obesity nutrition gerd esophageal ph-impedance food frequency questionnair
sacral neuromodulation test with bilateral first stage tined lead procedure in patients with non-obstructive urinary retention: a pilot study

Conditions: Urinary Retention

Summary: the objective of this study is to determine whether bilateral sacral nerve stimulation with first stage tined lead placement test is more effective than unilateral stimulation, among patients with non obstructive urinary retention.


Eligibility criteria:
inclusion criteria: * patients who signed the informed consent * patients (male and female), aged between 18-70 years, with non obstructive urinary retention. two specific subcategories of retention are included 1. incomplete voiding or incomplete retention (\>100 cc residual) such as hesitancy or intermittency, that are due to an acontractile detrusor or due to urethral sphincter overactivity. the overactivity of the sphincter may occur in absence of detrusor contraction and may be the cause of the lack of detrusor activity. 2. complete retention. these individuals are completely unable to void. all patients must have the potential for storing an adequate volume of urine: i.e., at least 100 ml exclusion criteria: * known psychiatric disorders * current or plans of pregnancy * known neurologic diseases or impairment; including dm (severe or uncontrolled diabetes; or diabetes with peripheral nerve involvement), spinal cord injury, ms * reiter's syndrome * concomitant medical conditions that would limit the success of the procedure such as: active degenerative disc disease, spinal cord injury\< 6 months old, bleeding complications, cva\< 6 months old etc. * extra urethral incontinence * pelvic pain of uncertain etiology that is not associated with a voiding dysfunction or where pelvic pain is the primary complaint/ diagnosis. * anatomic obstructive voiding disorders * current urinary tract infection * malignancy of urinary tract * severe grade iii/ iv pelvic prolapse, cystocele, urethrocele, enterocele * proven interstitial cystitis or clinical symptoms of interstitial cystitis

Keywords: sacral neuromodulation therapy urinary retention screening non obstructive urinary retention
effects of helicobacter pylori eradication in children with chronic immune thrombocytopenic purpura

Conditions: Immune Thrombocytopenia

Summary: thrombocytopenia refers to a reduction in platelet count to (\<150 × 109/l). immune thrombocytopenic purpura is an acquired autoimmune disorder defined by isolated thrombocytopenia and the exclusion of other causes of thrombocytopenia

helicobacter pylori was recently demonstrated as an etiological factor in immune thrombocytopenic purpura in some prospective studies, with reports of platelet numbers increasing in these patients after helicobacter pylori eradication treatment.however, other studies have shown a negative result after eradication treatment of helicobacter pylori infection in patients with chronic immune thrombocytopenic purpura, leading to controversy.

Eligibility criteria:
inclusion criteria: 1. chronic immune thrombocytopenic purpura patients who still have thrombocytopenia \> 12 months 2. age \<18 years . 3. diagnosis of immune thrombocytopenic purpura according to american society of hematology criteria based on an initial platelet count \<100×103/μl . 4. patients diagnosed as steroid and immunoglobulin resistant chronic immune thrombocytopenic purpura . exclusion criteria: 1. patients with acute immune thrombocytopenic purpura . . 2. age \>18 years. 3. thrombocytopenia was related to autoimmune disorders, drugs, a family history consistent with inherited thrombocytopenia, human immunodeficiency virus infection, hepatitis. 4. previous history of helicobacter pylori eradication; and history of medication with proton pump inhibitors, h2- receptor antagonists, or antibiotics in the previous 4 weeks.
alternative of treatment in obesity hypoventilation syndrome

Conditions: Obesity Hypoventilation Syndrome

Summary: primary objectives: evaluate the efficacy of noninvasive ventilation (niv) treatment versus continuous positive airway pressure (cpap) and life style modification treatment in obesity hypoventilation syndrome (ohs), with pco2 (first phase) and days of hospitalization (second phase) analyzed as a primary variables and percentage of dropouts for medical reasons and mortality as operative variables. as secondary variables: measure functional and clinical improvement during sleep and wakefulness, quality of life, echocardiography and the incidence and blood pressure and evolution of cardiovascular events. objectives secondaries:role of apneogenic sleep events on molecular inflammation, endothelial damage and the genesis of diurnal hypercapnia. methods:prospective, randomized controlled trial. patients with ohs will be divided initially into two groups based on their apnea-hypopnea index (ahi) score, \>=30 and \ =30 group will be randomized to cpap, niv or life style modification treatments. the ahi \<=30 groups will be randomized to niv or life style modification treatments. treatment efficacy at the medium- and long-term will be analyzed by comparing groups. the role of apneic events and leptin in the genesis of daytime alveolar hypoventilation will be analyzed by comparing the daytime pco2/ahi coefficient between responders and non-responders to cpap treatment, and the evolution of leptin levels in the four branches of the study. the role of apneic events in metabolic and biochemical alterations and endothelial dysfunction will be analyzed by comparing basal and post-treatment levels of related substances between groups, with and without significant ahi.

the ahi \>=30 group will be analyzed to cpap, niv or life style modification treatments for two mouths.once an evaluation is done during this period, the life style modification treatment will be randomized with the niv/cpap treatment for a continuation of three years.

Eligibility criteria:
inclusion criteria: * age between 15 and 80 years old. * absence of moderate or severe chronic obstructive pulmonary disease (copd). * absence of neuromuscular, chest wall or metabolic disease which cause daytime hypercapnia. * absence of narcolepsy or restless legs syndrome * exceed correctly treatment of at least 30 minutes with cpap/niv at wakefulness. exclusion criteria: * psychophysical incapacity to answer questionnaires. * patients who are not able to be evaluated by means of quality of life questionnaires for suffering restrictive chronic disease previously diagnosed (neoplasy, chronic pain of any origin, renal failure, severe chronic obstructive pulmonary disease and any other restrictive chronic disease). * subjects with important chronic nasal obstruction that prevents from using cpap/niv. * informed consent not obtained.

Keywords: sleep apneas noninvasive ventilation cpap
wound complications in head and neck surgery

Conditions: Hypothyroidism; Surgery; Head and Neck Cancer; Wound Heal; Laryngeal Cancer; Laryngeal Fistula

Summary: this is a prospective observational study evaluating wound complications following head and neck surgery. patients undergoing major head and neck surgery will be included in the study. patients meeting eligibility criteria will be identified by members of the university of michigan head and neck oncology division of the department of otolaryngology. the primary aim of this study is to identify risk factors for poor wound healing as well as biologic markers associated with wound related complications in head and neck surgery. most specifically, this study evaluates the effects of thyroid hormone on wound healing. this study will also evaluate pre-operative labs and comorbidities as well as reconstructive factors, post-operative labs, and other variables associated with wound healing. all interventions regarding wound healing fall under current standards of care and standard practice. data regarding post-operative wound complications will be collected in a prospective fashion on the variables under study using study-specific datasheets. data sheet will be entered into a secure database for analysis.


Eligibility criteria:
inclusion criteria: * in both groups: subjects must be 18 years or older with biopsy confirmed cancer of the head and neck. exclusion criteria: * children and vulnerable populations are not eligible for participation. patients undergoing functional (non cancer related) surgery, patients who have undergone more than 1 course of radiation to the head and neck, patients with a history of thyroid cancer, patients presenting initially with a malignant fistula, patients with previous intolerance or allergy to levothyroxine, and patients without a cancer diagnosis are not eligible. patients may enroll if they are currently hypothyroid, but will be excluded from the study if thyroid function is not normalized by the time of surgery.

Keywords: salvage surgery head and neck cancer wound healing hypothyroidism levothyroxine
minocycline as neuroprotectant after aneurysmal subarachnoid hemorrhage

Conditions: Subarachnoid Aneurysm Hemorrhage

Summary: the purpose of this study is to determine the safety and efficacy of a drug minocycline in improving outcomes at 3 months after rupture of an aneurysm in the head.

prior to the drug: if you decide to take part in this study, you will have a brief interview about your medical history and any medications you are taking. you will have a medical and neurological examination, ct scan and/or an angiogram to look at the blood vessel and blood supply going to the brain, and blood samples drawn for a complete blood count, chemistry analysis and cardiac enzymes (to assess any recent damage to your heart). you will have a surgery or an image guided procedure to close your aneurysm. additionally, during the course of the study you may be asked to have a computerized tomography (ct scan) or magnetic resonance imaging (mri) if there is a necessity. these tests will reveal areas that might have been damaged in your brain. drug: if the tests show that you qualify as a candidate for this study, you will be randomly assigned (like a flip of a coin) to have either the minocycline drug or a dummy drug that looks the same but does not have the drug in it. for the first 7 days, the drug will be given as an injection two times a day and after that for 14 days once a day by mouth. rest of the care will be standard like in any aneurysm patient. we study the status of your blood vessel surrounding the brain with ultrasound daily to see if they have any narrowing. if the doctors find any narrowing, you will be treated to relive the narrowing. if you are discharged home at any point in the 21 days, you will be switch the oral drug and given the required drugs with instructions. follow up: before you are discharged from the hospital and at 7, 21, 30 and 90 days after the start of the drug, the following evaluations will be performed: a complete physical and neurological examinations. as part of this study, you are required to return to the hospital or to your physician at one (1), seven (7), twenty-one (21), thirty (30), ninety (90) days after stroke onset. you will have a physical exam, a complete neurological exam. additionally, you will be asked questions about any health problems or hospitalizations you have had since you were discharged from the hospital.

Eligibility criteria:
inclusion criteria: * ≥ 18 yrs of age * ruptured aneurysm * initiate treatment within 72 hours of sah * pre rankin ≤ 1 exclusion criteria: * hunt \& hess 5 with no improvement * icp \> 30 * no plans to treat aneurysm * allergy to tetracycline / antibiotics * creatinine \>2 * platelets \< 75,000 * other brain diseases * previous infection requiring tetracycline

Keywords: sah
impact of sleeve gastrectomy on balance and cognitive function

Conditions: Effect of Sleeve Gastrostomy in Both Cognition and Balance

Summary: purpose of the study: purpose of study is to determine the effect of sleeve gastrectomy on balance and cognitive function in saudi arabia. aim of study: to investigate if there is any change of balance and cognitive function disturbance after sleeve gastrectomy on participant. research hypothesis: sleeve gastrectomy have no impact on balance and cognitive function. inclusion criteria: the participant will be selected according to the following criteria: 1.history of sleeve gastrectomy within 1 to 5 years. 2. their age between (20-60 years). 3.ability to walk without any assistive device. 4.all participant should be able to understand all requested instructions exclusion criteria: the participant will be excluded if they have: 1. any cognitive disturbances. 2. disease that may affect balance (spinal stenosis, peripheral polyneuropathy, vestibular impairment). 3. gastrectomy operation less than 1year. 4. pregnancy. material: 1. introduction survey (willingness of participant) to recruit sittable participant. 2. assessment form survey to collected data and result (include moca and app-coo application)


Eligibility criteria:
inclusion criteria: - the participant will be selected according to the following criteria: 1. history of sleeve gastrectomy within 1 to 5 years. 2. their age between (20-60 years). 3. ability to walk without any assistive device. 4. all participant should be able to understand all requested instructions exclusion criteria: - the participant will be excluded if they have: 1. any cognitive disturbances. 2. disease that may affect balance (spinal stenosis, peripheral polyneuropathy, vestibular impairment). 3. gastrectomy operation less than 1year.

Keywords: sleeve gastrectomy balance cognition
impact of dose to cardiac substructures on survival in patients with esophageal cancer treated with radiotherapy or chemoradiotherapy (satiation)

Conditions: Esophagus Cancer

Summary: treatment of non-operable esophageal cancers is based on radiochemotherapy, or exclusive radiotherapy. the cardiac toxicity of radiotherapy in the treatment of thoracic tumor localizations is well documented, however, more and more studies are calling for the use of dosimetric parameters related to cardiac sub-structures to be integrated into clinical practice, rather than considering the heart as a whole. with this in mind, the aim of this study is to define the parameters, particularly dosimetric ones linked to cardiac sub-structures, influencing survival in patients treated with exclusive radiotherapy or radiochemotherapy for esophageal cancer.

treatment of non-operable esophageal cancers is based on radiochemotherapy, or exclusive radiotherapy. the cardiac toxicity of radiotherapy in the treatment of thoracic tumor localizations is well documented, however, more and more studies are calling for the use of dosimetric parameters related to cardiac sub-structures to be integrated into clinical practice, rather than considering the heart as a whole. although most of these data have been studied in populations with long-term follow-up, such as breast cancer, cardiac toxicity and the reduced survival it entails are also found in diseases such as esophageal cancer. with this in mind, the aim of this study is to define the parameters, particularly dosimetric ones linked to cardiac sub-structures, influencing survival in patients treated with exclusive radiotherapy or radiochemotherapy for esophageal cancer.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * histologically or cytologically proven esophageal cancer * localized or locally advanced esophageal cancer treated with radiochemotherapy or exclusive radiotherapy * tumor dose ≥ 50 gy * non-opposition of living patients formulated * patient affiliated to a social security scheme exclusion criteria: * age \< 18 years * patient treated with upfront surgery * tumor dose \< 50 gy * other concomitant neoplasia * metastatic patient * refusal to participate * patient under legal protection (guardianship, curatorship, etc...)

Keywords: radiotherapy; cardiotoxicity
allogeneic use of expanded mesenchymal stem cells derived from adipose tissue (hc106), female urinary incontinence women over 50 years old

Conditions: Urinary Incontinence Stress

Summary: evaluate the feasibility and safety, obtaining initial efficacy data, of expanded allogeneic mesenchymal stem cells derived from adipose tissue (hc106) for the treatment of urinary incontinence in women over 50 years of age.

it's a controlled trial, in phase i, proof of concept, safety and preliminary analysis of efficacy. it is planned to make 2 cohorts of patients, one with a single dose of 40 million hc016 and another group with saline solution (control).

Eligibility criteria:
inclusion criteria: * women over 50 years old * women with a clinical diagnosis of genuine or mixed stress urinary incontinence (sui) with at least 6 months of evolution. using the definitions of urinary incontinence internationally accepted by the ics (international continence society): to. sui: any involuntary loss of urine, immediately preceded by exertion. b. mixed ui: any involuntary loss of urine, immediately preceded by exertion or an uncontrollable desire to urinate. the predominance of effort will be assessed when more than 50% of the patient's daily losses occur preceded by effort. * women in whom rehabilitative treatment has failed or patients who refuse to undergo rehabilitative or surgical treatment * patients without active urinary tract infection (negative urine culture) at the time of recruitment and treatment * signing of the informed consent form exclusion criteria: * patients with a medical history of previous surgery for incontinence, prolapse or urological/gynecological/colorectal surgery * major surgery or serious trauma of the subject in the previous semester * women with mixed urinary incontinence, with predominant symptoms of urgency * history of high-pressure detrusor overactivity * present infravesical obstruction, vesico-ureteral reflux or clinical history of urinary fistula (it will be ruled out depending on the case by urethrocystoscopy, urethrocystography and flowmetry). * present any malignant neoplasm, unless it is basal cell or squamous cell carcinoma of the skin, or present a history of malignant tumors, unless they have been in remission during the previous 5 years. * cardiopulmonary disease that, in the opinion of the investigator, is unstable or serious enough to exclude the patient from the study. * medical or psychiatric illness of any type that, in the opinion of the researcher, may be a reason for exclusion from the study. * history of alcohol or other addictive substance abuse in the 6 months prior to inclusion * subject's allergy to anesthetics
study to assess the efficacy and safety of dysport® in the treatment of chronic plantar fasciitis

Conditions: Chronic Plantar Fasciitis

Summary: this study will investigate the hypothesis that the analgesic effect of a single injection of dysport (200 mu) induces a significant reduction of symptoms in chronic cases of plantar fasciitis.


Eligibility criteria:
inclusion criteria: * chronic plantar fasciitis (duration of disorder at least 4 months) * at least 4 points on the visual analogue scale (0-10) for the most severe pain within the last 48 hours * at least 2 previous unsuccessful conservative therapies * age 18 and older exclusion criteria: * rheumatoid diseases (m. bechterew, chronic polyarthritis, psoriasis-arthritis, para /post-infectious arthritis etc.) * previous surgery in the affected area of the foot * pre-treatment with botulinum toxin a (only de novo patients) * prohibited concomitant treatment: local injections during the study and 2 weeks prior to start of study